Cancer Research
FDA Approves Keytruda Combo for Platinum-Resistant Ovarian Cancer
Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.
Drug Approval
Apr 20, 2026 0
Cancer
15 articles in this topic
Cancer Research
FDA Approves Zongertinib for HER2-Mutant Lung Cancer in Landmark Targeted Therapy Win
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
Drug Approval
Apr 20, 2026 0
Cancer Research
FDA Approves Zongertinib for HER2-Mutated Lung Cancer in February 2026
New targeted therapy offers hope for patients with specific genetic mutations in non-small cell lung cancer.
Drug Approval
Apr 15, 2026 0
PreviousPage 2 of 2